Reimbursed Care Access in Afghanistan

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Afghanistan does not have an identifiable regulatory/market authorization pathway or reimbursement mechanism for psilocybin‑based therapies; possession, manufacture, or distribution would be treated as illicit under Afghan narcotics enforcement practice and the de facto authorities’ strict drug controls. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public reimbursement, no approved clinical programme for MDMA‑assisted therapy, and no publicly reported registered clinical trials operating in Afghanistan. #.

Esketamine (spravato) does not appear to be authorized, available, or reimbursed in Afghanistan through any national regulatory or public insurance mechanism; Afghanistan lacks an operational medicines‑authorization and reimbursement infrastructure comparable to high‑income regulators, and there is no evidence of a market introduction or public reimbursement for esketamine products in the country. As a result, esketamine would be effectively unavailable except possibly within a formal international clinical trial (none publicly documented) or through exceptional importation to private facilities — both highly unlikely in practice. For context on the extremely limited medicines financing and absence of a national, universal reimbursement scheme in Afghanistan, see analyses of Afghanistan medicines financing and health financing constraints. # #.

Ketamine is listed on the WHO Model List of Essential Medicines as an injectable general anaesthetic and is used globally — including in low‑resource and conflict‑affected health systems — as a core anaesthetic agent; this global status supports its clinical availability in Afghan hospitals and clinics where basic surgical/anaesthesia services are provided. # #.

Regulatory and reimbursement context in Afghanistan: Afghanistan does not maintain a comprehensive national pharmaceutical reimbursement or universal health insurance programme that covers specialised psychiatric therapeutics; medicines financing is fragmented and heavily donor‑dependent, and most non‑essential medicines are obtained through private purchase or NGO supply channels. As a practical consequence, ketamine is used primarily as an anaesthetic agent in public and NGO‑run facilities where available, but there is no structured national reimbursement pathway for ketamine when used as part of emerging psychiatric‑research protocols (e.g., for treatment‑resistant depression), and access for psychiatric indications would be off‑label and institutionally dependent. #.

Operational nuances: supply of injectable ketamine in Afghanistan is dependent on humanitarian supply chains, local procurement capacity, and the presence of trained anaesthesia providers. Given the country’s recent political changes and constraints on the health sector, routine public reimbursement for specialty psychopharmacology (including off‑label psychiatric ketamine infusions or esketamine nasal spray) is not available; any such treatments would be limited to private actors or international clinical projects that secure their own funding and importation approvals. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public framework for therapeutic DMT provision or reimbursement in Afghanistan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No authorized clinical programmes or reimbursement pathways exist in Afghanistan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of legal, reimbursed ibogaine treatment availability or clinical trial activity in Afghanistan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The traditional brew (ayahuasca) contains DMT and would therefore be treated as illicit under Afghan narcotics controls; there is no legal medical or reimbursed access. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no recognized medical programmes, approved indications, or reimbursement mechanisms for mescaline in Afghanistan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No lawful clinical or reimbursed access exists in Afghanistan for 2C‑series compounds. #.